

# Earnings Presentation
# Q1’FY27

# Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

# Jubilant Bhartia Group has created value across multiple sectors


## Strong presence in diverse sectors

- Pharmaceuticals
- Life Science Ingredients
- Performance Polymers
- Food Service (QSR)
- Beverages
- Contract Research & Development Services
- Therapeutics
- Auto Dealerships
- Oil and Gas services

## Global presence through investments

- India
- USA
- Canada
- Europe
- Singapore
- Australia
- Africa
- China
- Sri Lanka, Bangladesh

## Employer of Top Talent

56,000 people across the globe with ~2,200 in North America

# Jubilant Pharmova, a diversified pharmaceutical company

## Radiopharma

**Leading manufacturer**
of Radiopharmaceuticals
in North America
2nd largest radiopharmacy network in the US

## Allergy Immunotherapy

**2nd largest player**
in the US Allergenic extract market
Sole supplier of Venom
Immunotherapy in the US

## CDMO Sterile Injectables

**Leading contract manufacturer**
in North America
Serves top global innovator pharma companies

## CRDMO

**Integrated drug discovery**
and development service provider
Formidable API player
in multiple therapeutic areas

## Generics

**Over 50 countries served**
including regulated markets
Broad therapeutic areas :
CVS, CNS, GI and MS



## Proprietary Novel Drugs

**Two drug programs**
in clinical trials
Developing high potential precision medicines in Oncology

**A global leader with a strong team of 5,500 people**

# Focus on specialty products & services and Dollar revenues

## Business wise Revenue Split

*Q1'FY27*




**Specialty Products (Radiopharma, Allergy Immunotherapy) – 56%**
**and Specialty Services (CDMO & CRDMO) – 36%**
**contribute majority of revenues**

## Currency wise Revenue Split

*Q1'FY27*




**Majority revenues are USD denominated**

# Minimal risk from US Tariffs

## Geography wise Revenue Split

*Q1'FY27*




**US market constitutes majority of revenues**

## Origin of Goods & Services sold in the US

*Q1'FY27*


**Goods from Canada (Radiopharmaceuticals) exempted from tariffs under US- Canada – Mexico trade agreement**

* Goods and Services from Canada 14% : Goods 14%, Services 0%
* Goods and Services from India 8% : Goods 3%, Services 5%

# State-of-the-art manufacturing and research facilities enable our growth

**NORTH AMERICA**

Kirkland, Montreal, Canada
CDMO – Sterile Injectables  Radiopharmaceuticals


Spokane, Washington, US
CDMO – Sterile Injectables  Allergy Immunotherapy


**INDIA & EUROPE**

Roorkee, Uttrakhand, India - Generics


Nanjangud, Karnataka, India - CDMO API



G. Noida, Uttar Pradesh - Drug discovery

Bengaluru, Karnataka - Drug discovery

France - Drug discovery

**6**
**Manufacturing facilities**

**3**
**Research facilities**

**45**
**Radiopharmacies**

# Vision 2030: We aspire to double our revenues by FY30 and we are on the right track

| | *From* FY24 | → *To* FY30 | *Actual* TTM Q1'FY27 |
|---|---|---|---|
| **2x** Revenue | Rs. 6,703 Cr. | **Rs. 13,500 Cr.** | **Rs. 8,608 Cr.** |
| **25%** EBITDA Margin | ~ 15 % | **23% to 25%** | **15%** |
| **Zero** Net Debt | Rs. 2,457 Cr. | **Zero** | **Rs. 2,332 Cr. End of Q1'FY27** |
| **High Teens** RoCE | High Single digit | **High Teens** | **11%*** |

- ( EBIT before exceptional items ) / Average ((Equity + Gross Debt ) less (CWIP adjusted for grant))

# These are our growth drivers to achieve Vision 2030

| Business | Growth Drivers | Progress in Q1'FY27 |
|---|---|---|
| Radiopharma | **Leadership** in Ruby-Fill®<br>**Launch New** PET, SPECT and Therapeutic products (MIBG)<br>**Invest in 6 high margin** PET Manufacturing facilities in US | Ruby-Fill® growth at **26%**<br>Development Progressing<br>Investment on track |
| Allergy immunotherapy | **Strengthen competitive position,** develop new products | **Gaining Market Share in US** |
| CDMO - Sterile Injectables | **Double capacity** in Spokane, US | Line 3 **Peak Revenue** by FY28<br>**Line 4 installation** complete |
| CRDMO | **Add large pharma** customers<br>**Grow CDMO** and custom manufacturing in API | Custom manufacturing revenue increasing |
| Generics | **Launch new products** in the US and Grow profitable Non-US international business | **Launched 2 new products** |


Radiopharma

# Radiopharmaceuticals

**SPECT Imaging**

**Low Energy**
gamma rays
detected by SPECT cameras

**PET Imaging**

**High Energy**
positrons
detected by a PET scanner

**Radiopharmaceutical Therapeutics**

**Systemically or Locally Delivered**
radiation using pharmaceuticals

| | | | |
|---|---|---|---|
| | Isotopes - Tc99m | Isotopes - Rb82, F18, Ga68 | Isotopes – I131, Lu177, Ac225 |
| **Key Products** | MAA, DTPA, Sulfur Colloid, Mertiatide | Ruby-Fill ®, Pylarify, Illuccix, Neuraceq, FDG | HICON® Sodium Iodide I 131, Pluvicto, Lutathera |

**Radiopharmaceuticals have a growing role in treatment of life-threatening diseases** *e.g. Cancer*

# US Radiopharmaceutical market is growing at rapid pace

**US Radiopharmaceutical Market**
*USD Bn.*




## Growth Drivers & Trends

**Launch of advanced Therapies**

- PSMA Therapeutic, Pluvicto for Prostrate Cancer ~USD 2.0 Bn.

**New products in PET Imaging**

- PSMA Diagnostics for Prostrate Cancer ~ USD 1.8 Bn.
- Broad range of applicability e.g. Alzheimer's
- Special reimbursement for diagnostic products (FIND Act)

**Multiple billion-dollar M&A deals**

- Novartis and Mariana Oncology (USD 1 Bn.)
- AstraZeneca and Fusion (USD 2.4 Bn.)
- Lilly and Point Biopharma (USD 1.4 Bn.)
- BMS and Rayzebio (USD 4.1 Bn.)
- BMS and Philochem (USD 1.4 Bn)

**PET imaging & advance therapies are driving the market growth**

# Jubilant Radiopharma – Integrated player with Radiopharma Development, GMP Manufacturing and distribution network

## Radiopharmaceutical Plant, Montreal, Canada

## 2nd largest Radiopharmacy Network, US




- Integrated development and manufacturing site with decades of experience in radiopharmaceutical manufacturing
- Ability to handle multiple isotopes:
  - Diagnostic isotopes : F18, Ga68, Tc99, Rb82, I131Dx
  - Therapeutics isotopes : I131
  - Leader in SPECT products - MAA, DTPA, Cardiac PET product - Ruby-Fill® &Therapeutic I-131HICON®
- Deep pipeline in SPECT / PET assets with upcoming launches
- Final stages of filing for I-131 MIBG ( Neuroblastoma )

- Network of 42 Nuclear Radiopharmacies and 3 PET Manufacturing facilities
- Serves 1,800 hospitals with 6 customized doses delivered every minute
- Distributes diagnostic radiopharmaceuticals spanning Tc-99, Ga-68, F18, Cu64, I131 and I123
- Expanding the PET manufacturing network from 3 to 9 locations in the US by FY28
- One of the only two pharmacy networks dispensing Lu-177 therapy in the US for Novartis

# Solid foundation in SPECT Imaging, Poised to develop PET imaging agents & the supply chain for PET and Therapeutics

Integrated platform across the value chain

| | SPECT | PET | Therapeutics |
|---|---|---|---|
| Product | • **Strong and growing** product portfolio | • **Rapidly growing Cardiac Imaging franchise** and a robust pipeline including pet assets | • **80% share in I-131**<br>• Undergoing Clinical Trials for I-131 MIBG in Neuroblastoma |
| Radio - labeling | • **2nd largest network of 42 radio pharmacies** distributing ours & industry products across 21 states<br>• Continuing to build to serve nationally | • **3 operational PET manufacturing facilities with 6 more** in deployment<br>• Deep experience including ownership and optimization of Sofie platform | • **Operate one of the few** approved CFR 211 radiopharmaceutical manufacturing sites in North America |
| Last Mile Delivery | • Owned fleet of ~400 vehicles to ensure high quality timely delivery and waste management<br>• **Currently servicing 1,800 customers** at nearly 3,000 individual locations | • **Integrated with SPECT platform** to ensure a single seamless delivery to multi modality sites and drive operating efficiencies | • **One of the two networks dispensing Lu177** PSMA Therapy<br>• Plan to equip more pharmacies in the network to increase reach in Beta emitter therapy dispensing & hub and spoke model for Alphas |

# Consolidated Market with high Entry Barriers

### *Stringent manufacturing & regulatory environment*

Adherence with **extensive license framework.** Stringent manufacturing set up required to handle isotopes

### *Managing time sensitive logistics*

**Radioactive isotope decays exponentially.** The half life could be few hours to few days. Goal is to deliver high activity doses

### *Forward integration with radiopharmacies*

Forward integration with radiopharmacies **helps to gain market share**

### *Innovative new product development*

**High capex requirement, long developmental cycle** and **complex isotope handling requirements** for novel product development.

# We are a leading Radiopharmaceuticals manufacturer in North America

| | Organ | Key Indication | Product |
|---|---|---|---|
| **PET Dx** | Cardiac | Coronary Artery disease | Ruby - Fill® |
| **SPECT Dx** | Breast | Lymph nodes detection | Sulfur Colloid |
| | Cardiac | Cardiac blood pool imaging | Tc99m-Gluceptate |
| | | Coronary Artery Disease | Tc99m-Sestamibi |
| | Gastrointestinal | Intra-abdominal Infection | Tc99m-Exametazime |
| | Lung | Pulmonary Embolism | Tc99m-DTPA |
| | | Pulmonary Perfusion | Tc99m-MAA |
| | Muscoskeletal | Altered osteogenesis | Tc99m-MDP |
| | Renal | Renal failure | Tc99m-Mertiatide |
| | Thyroid | Localising thyroid malignancies | I-131 |
| **Therapeutics** | Thyroid | Hyperthyroidism, Thyroid Cancer | I-131 HICON® |

- **Diversified across diagnostics & therapeutics**
- **Current TAM at USD 400 Mn.**
- **Strong R&D and supply chain**
- **In-house API manufacturing**

# Market leadership in select products

## Draximage ® MAA


MAA is used in the perfusion phase of a ventilation/perfusion (V/Q) scan to diagnose pulmonary embolism. JDI is leading player in the US market

## Draximage ® DTPA


DTPA is used to assess pulmonary ventilation function in association with MAA to perform a Ventilation/perfusion (V/Q) scan. JDI is leading player in the US market

## Ruby-Fill ®

It is used for Cardiac PET scan, to evaluate regional myocardial perfusion in adults with suspected or existing coronary artery disease. JDI is the innovative leader in the US market

## HICON® Sodium Iodine I 131 Solution USP

HICON® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid. JDI has no direct competition in the US market

# Radiopharmaceuticals Financials : Q1'FY27

| Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 271 | 319 | 322 | *19%* |
| EBITDA | 126 | 106 | 110 | *(13%)* |
| *EBITDA Margin (%)* | *46%* | *33%* | *34%* | *(1,250) bps* |

- Revenue grew strongly on back of growth in Ruby-Fill ®
- EBITDA margins decreased YoY due to unavailability of high margins SPECT products
- At CMO Montreal, Commercial batch production started, Batches to be released in Q2'FY27
- Revenue and EBITDA to normalize from H2'FY27 onwards

# Radiopharmaceuticals Vision 2030: To more than double the revenues

EBITDA margins impacted by unavailability of high margin SPECT Products due to lower production at CMO Montreal. To improve post H2'FY27, once supply normalizes

EBITDA margins to further improve post the new products introduction starting from FY28

Revenue:
**More than 2x of FY24**

EBITDA Margin:
**More than 50%**




**Growth drivers:**

- **Ruby-Fill®**
- **New PET & SPECT products**
- **MIBG**

# To become leader in cardiac PET Imaging through Ruby-Fill®

Growth drivers:

- Ruby-Fill®
- New PET & SPECT products
- MIBG

**Ruby-Fill ® Rubidium 82 generator and Elusion System**

**Competitive advantage**

- Longer life per generator (7 weeks vs 6 weeks for peer)
- Better image quality and consistency
- Constant Activity
- Higher number of scans per day vs Fluorine 18 labelled agents
- No additional shielding capex vs Fluorine 18 labelled agents

**Current Position**

- US Market Size ~ USD 200 + Mn. and growing at 12%
- Market share ~ 25 to 30% and growing
- Margin improving every year

**Product Innovation**

- AI enabled 3D cardiac blood flow quantification

**26% annualized growth in install base in Q1'FY27**

# Launch new PET and SPECT imaging products with a TAM of USD 535 Mn

Growth drivers:

- Ruby-Fill®
- New PET & SPECT products
- MIBG

## Developing new products in SPECT Imaging to maintain leadership & in PET Imaging for growth

| Timeline | Incremental TAM USD Mn. | Potential Peak Annual Sales USD Mn. | No. of Launches |
|---|---|---|---|
| FY28 | 260 | 85 | 3 |
| FY29 | 275 | 55 | 4 |
| **Total** | **535** | **140** | **7** |




**Revenue Potential increased to 140 Mn., Progress on track**

# Launch MIBG by CY27

**Growth drivers:**

- **Ruby-Fill®**
- **New PET & SPECT products**
- **MIBG**

**HICON® Sodium Iodide I 131 -** Commercialised

- Iodine I 131, HICON® is standard care for patients
- Used for diagnosis and treatment of Thyroid cancer

**MIBG -** Undergoing Clinical trials




- Used in imaging & treatment for pediatric cancer - Neuroblastoma
- Relapsed / Refractory patients have limited treatment options

- **Potential peak sales USD 70 - 100 Mn.**
- **NDA filing post FDA meeting by H2'FY27**

# Radiopharmacy

# Radiopharmacies are critical in generating value

**SPECT Radiopharmacy**

**PET Manufacturing Facility**

## Growth Drivers & Trends

- **Consolidated market in the US. Large M&A transactions** in Radiopharmacies
- **Increasing demand for novel PET products** driving PET radiopharmacies growth
- **Stringent USP 825 regulations** to drive increase in therapeutics dispensing through Pharmacy
- **Emerging radioisotopes landscape** such as Ga-68, Cu-64, Lu-177, Ac-225

# Consolidated market with high Entry Barriers

## Consolidated Market

| | # of radio pharmacies in the US | SPECT Pharmacies | PET Manufacturing Facility | # of hospitals served in the US |
|---|---|---|---|---|
| CardinalHealth | 160+ | ✓ | ✓ | ~ 4,100 |
| Jubilant Radiopharma | **45** | ✓ | ✓ | ~ 1,800 |
| Siemens Healthineers PETNET Solutions | 41 | | ✓ | ~ 700 |
| RLS | 31 | ✓ | | ~ 900 |
| PharmaLogic Take The Lead | 42 | ✓ | ✓ | ~ 200 |
| SOFIE | 14 | | ✓ | ~ 200 |

## Barriers to Entry

1. **Stringent Regulations**
   Each treatment site is required to obtain a license from Nuclear Regulatory Commission and comply with additional state, local, and hospital regulations for transportation and usage

2. **Intricate Supply Chain**
   A robust supply chain is required given short product half-lives and strong customer preference for just-in-time ordering, compared to large bulk orders

3. **Complex Care Coordination**
   Requires awareness, education, and collaboration across multiple hospital departments

4. **Skilled Manpower Requirement**
   Authorized nuclear pharmacists require at least 4,000 hours of training or experience in nuclear pharmacy practice along with rigorous examinations

# The 2nd largest radiopharmacy network in the US

**45**
Radiopharmacies with ~ **20%** volume market share

**1,800**
hospitals catered

**6** customized doses delivered **every minute**

**99%+**
on-time deliveries, Use of AI for route optimization




**USP<825>**
*JDR network is USP 825 compliant*

**Business moat**
Unique combination of SPECT manufacturing & radiopharmacy network

**6**
Planning new sites in PET network

**Therapeutics**
distribution is preferred from radiopharmacies

# Radiopharmacy Financials : Q1'FY27

| Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 598 | 671 | 700 | *17%* |
| EBITDA | 10 | 11 | 12 | *19%* |
| *EBITDA Margin (%)* | *2%* | *2%* | *2%* | *0 bps* |

- Revenue grew YoY on the back of increase in volume from certain PET products. High competitive intensity in SPECT continues
- EBITDA grew YoY on the back of increase in revenue. Expect margin pressure going forward due to high competitive intensity in SPECT products

# Radiopharmacy Vision 2030: Double the revenues, expand margins by adding 6 PET Manufacturing Facilities

Revenue:
**2x of FY24**
EBITDA Margin:
**~ 7% to 8%**



# Expanding PET Manufacturing Facilities from current 3 sites to 9 sites

**Growth driver:**

- **PET expansion**


- **Strengthened network to enable long term contracts** with PET radiopharmaceutical manufacturers
- **Fully operational by FY28**. Funding through internal accruals and long-term credit
- **Investment of USD 60 + Mn.**

**Continue to witness increase in revenues from the 3 existing PET Manufacturing facilities**


Allergy
Immunotherapy

# Allergy immunotherapy is the sole way to fundamentally reduce allergen hypersensitivity

- 20% + global population have allergies e.g. Asthma and Allergenic Rhinits
- Allergy Immunotherapy requires repeated shots of allergic antigens to develop immunity

**Allergies**

**Testing**



**Treatment**

# Global Allergy Immunotherapy market is expected to grow by ~ 7%

**Global Allergy Immunotherapy Market**
*USD Bn.*




## Growth Drivers and Trends

- **Concentrated US market** with 3 players
- **Complex supply chain** from sourcing to processing
- **Grandfathered approvals**, new product needs BLA
- **Market increasing** in Sub-Lingual delivery
- **Challenging reimbursement** landscape

# 2nd largest player in the US Sub-Cutaneous Allergy Immunotherapy market

- **100-year-old 'HollisterStier'** brand
- **Sole Supplier** of Venom extracts in the US
- **200+** allergenic & **6** venom extracts
- **Onshore US FDA approved** manufacturing
- **Dedicated sales force in the US**
- **2,000+ Allergists / ENTs** as customers

## Venom Extracts

Venom extracts for Honey Bee and other insects

## Allergenic Extracts

Allergenic extracts for Dog, Cat, Mite, Tree, Pollen etc.

## Skin Testing Devices


Multiple skin testing systems

# Allergy Immunotherapy Financials : Q1'FY27

| Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 181 | 218 | 214 | *18%* |
| EBITDA | 63 | 90 | 66 | *5%* |
| *EBITDA Margin (%)* | *35%* | *41%* | *31%* | *(400) bps* |

- Revenue grew on the back of growth across US & Outside US markets
- EBITDA margin lower YoY due to lower production.

# Allergy Immunotherapy Vision 2030: Solidify position as a scientific leader




Revenue:
**~1.5x of FY24**
EBITDA Margin:
**35% to 40%**

# Allergy Immunotherapy Growth Drivers

## Strengthen competitive position in US

- **Retain and grow Venom customers** & patient base
- **Increase US revenue in Allergenic extracts** through targeted marketing

## Grow outside US business

- **Increase outside US Venom sales** through strategic partnerships in European markets

## Increase investment in R&D

- **Develop new products** & technologies
- **Build treatment innovation** through partnerships and alliances

# CDMO - Sterile Injectables

# CDMO - Sterile Injectables is seeing demand supply gap widening

**Global CDMO-SI Market Size**

*USD Bn*




**Vial filling ( Units in Billions )**

| Year | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| Demand | 4.9 | 5.2 | 5.7 | 6.2 | 6.8 |
| Supply | 5.5 | 5.8 | 6.1 | 6.1 | 6.1 |

**Demand supply gap of 700 Mn. vials in 2027, to be further widened by industry consolidation**

## Growth Drivers & Trends

- **Innovator Pharma companies, for their US requirement, are planning to shift the manufacturing** from Europe to US, as a risk mitigation measure due to impending Tariffs by the US Govt.
- **Consolidation in supply** due to large acquisitions - Catalent Inc. by Novo Holding
- **Increasing number of drugs** in Biologics pipeline and Loss of exclusivity
- **Reduction in offshoring** by innovators due to regulatory and supply chain advantages

# Market with high Entry Barriers



- **Majority of commercial contracts are typically long duration** (typically 3 years or more with auto renewal)
- **Greenfield expansion is considerably difficult** due to high up-front capex required with ongoing opex to support initial product commercialization
- **Innovator companies prefer onshore North American manufacturers** with a good quality track record in light of continuing supply challenges
- **Attractive niches & Technology** (e.g., Isolator Technology, Multi Dose Preservative Free ophthalmic drops, etc.) have emerged, driven by requirements of differentiated technologies, higher quality standards, people capabilities and capital investment
- **High switching costs for customers** due to significant tech transfer time (18-24 months), other challenges, e.g., quality
- **Stringent regulatory requirements (FDA) for sterile manufacturing**, with ever evolving landscape making difficult for new entrants

# We are a leading North American CDMO player with unique capabilities and strong customer relationships

- **5 of the top 20** pharma companies as customers
- **25+** customers across the world with multiple products having patent protection and limited competition
- **5+ years** average relationship time with Top 10 Customers
- **90%+ repeat customer** business
- **24 months** of switching timelines for customers
- **Full suite of services** including sterile fill and finish (Liquid & Freeze dried), Ophthalmic (Liquids and Ointments) and Biologics
- **10+ years of US FDA compliant status** at flagship site in Spokane

**The business is engaged in Fill and Finish for Sterile Injectables, where a sterile drug is transferred from a filling needle into a sterile vial and then a stopper is applied, except in cases, where the drug requires sterile lyophilization.**

# CDMO Sterile Injectables Financials : Q1'FY27

| TOTAL<br>Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 370 | 535 | 496 | *34%* |
| EBITDA | 62 | 91 | 45 | *(28%)* |
| *EBITDA Margin (%)* | *17%* | *17%* | *9%* | *(780) bps* |

| SPOKANE<br>Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 346 | 532 | 494 | *43%* |
| EBITDA | 78 | 166 | 117 | *49%* |
| *EBITDA Margin (%)* | *23%* | *31%* | *24%* | *100 bps* |

- Revenue grew strongly on YoY due to incremental revenues from Line 3 at Spokane. Revenue lower QoQ due to planned maintenance shutdown
- EBITDA margin lower YoY due to negligible third-party revenues & higher operating expenses including incremental remediation cost at CMO Montreal
- Spokane revenue grew strongly on the back of scale up of Line 3, scaling up faster than the industry benchmark. Revenue lower QoQ due to planned maintenance shutdown
- Spokane EBITDA margin expanded YoY on the back of best-in-class revenue growth

# CDMO - Sterile Injectables Vision 2030 : Double revenues by doubling of capacity at Spokane

Revenue expected to overshoot Vision target

EBITDA margins to improve with reduction of losses at CMO Montreal

Revenue :
**More than 2x of FY24**
EBITDA Margin :
**More than 25%**



# Line 3 Technology transfer revenues continue to grow Commercial Batch Production expected to start in FY27

**Growth driver:**

- **Doubling Capacity at Spokane**

| Timeline | FY'26 | FY'27 | FY'28 |
|---|---|---|---|

**LINE 3**

*Tech Transfer Start of Revenues*

*Commercial Batch Production post FDA approval*

*Moving to Peak utilization*

- **Line 3 revenues scale up is one of the fastest in the industry on the back of 10+ technology transfer programs**
- **Expect commercial batch production to start in FY27; To reach full utilization in 3 ½ years**
- **Peak revenue potential of USD 80 to 90 Mn.**

# Line 4 installation on track
# Technology transfer revenues expected to start in FY27

**Growth driver:**

- **Doubling Capacity at Spokane**

| Timeline | FY'26 | FY'27 | FY'28 |
|---|---|---|---|

**LINE 4**

*Installation* — *Media Fill* — *Commercial Production*

- **Line 4 installation complete**
- **Building a strong order book pipeline**
- **Expect technology transfer revenues to start in Q4'FY27**
- **To reach full utilization in 3 ½ years**
- **Peak revenue potential of USD 80 to 90 Mn.**

# Line 5 to generate tech transfer revenues from FY29

**Growth driver:**

- **New Isolator Line at Montreal**

## New Isolator Fill & Finish Line ( Line 5 )

- **Construction started; Orders placed for Plant & Machinery**
- **Capex at USD 114 Mn., Concessional loan at USD 35 Mn.**
- **Expect Technology transfer revenue to start in FY29**
- **Scale up of revenue will be similar to Line 3 & 4**

## Existing Line

- **Production started for SPECT Radiopharmaceutical products.**
- **Remediation work is in progress, Engaged with FDA**
- **Continue lean operations in FY27 & FY28, till Line 5 becomes operational in FY29**

# With Line 3,4&5, We are becoming a specialized CDMO delivering complex biologics formulations for Innovators

## Traditional CDMO

- **Product Mix ~** 80% small molecules & **20% Biologics** with low formulation complexity
- **Capability** viewed as **volume driven CDMO**
- **Quality of Revenue:** **Lower technology transfer revenue**. Programs are easier to onboard and quicker to qualify

## Line 3, 4 & 5

- **Product Mix** projected at 20% small molecules & **80% Biologics** with complex formulations (e.g. advanced processing requirements & Technology Transfer packages, high-complexity and high value APIs)
- **Capability** includes **specialised filling**, **tighter aseptic processing windows** & stringent environment controls
- **Quality of Revenue:** **Higher technology transfer revenue** model. Programs are difficult to onboard & longer to qualify, once commercialised, more durable

**Onboarded one of the World's Largest Oncology products on Line 3**


CRDMO: Drug Discovery Services, CDMO API

# CRDMO: Drug Discovery, CDMO - API
# India uniquely positioned to benefit from Friendshoring

**Drug Discovery Services Market Size**

*USD Bn.*




**CDMO API Market Size**

*USD Bn.*




## Growth Drivers & Trends

### Drug Discovery Market

- Biosecure Act advantage
- Rise in specialized technologies such as ADCs and oligonucleotides

### CDMO API Market

- Rising interest in custom generics
- Rapid momentum in specialized CDMO services

# We are a leading CRDMO for science with superior customer relationships

- **~ One third revenue contribution** from Large Pharma accounts
- **Indian Leader for "Integrated Drug Discovery"**, with a track record of 100+ programs and Big pharma strategic partnership
- **Strengthen European penetration,** with multifold revenue increase
- **Fully integrated Chemistry powerhouse** from mg to multi-tons
- **Successful launch of new CDMO services** for Biotech and Large Pharma during the year

# …with Integrated Discovery & Development Infrastructure

## Drug Discovery

### Integrated Drug Discovery Center (Bengaluru, India)

**~400 Scientists**
**120+ IDD programs**

- Target ID to pre-clinical candidate selection with best-in-class drug discovery timelines
- Structural Biology, CADD, In Vitro, In Vivo Biology, DMPK, Toxicology
- AAALAC-accredited vivarium

### Chemistry Innovation Research Center (Delhi NCR, India)

**~750 Scientists**
**6 Centers of Excellence**

- Synthetic, Medicinal, Analytical & Computational Chemistry; DMPK, Biology
- Expertise in Degraders, Peptides, Lipids, Solid State, Library Synthesis, Photo Redox, Carbohydrates

### Center of Excellence for Biologics & ADCs (St. Julien, France)

**~35 Scientists**
**In the Pharma Hub of Europe**

- ADCs - Full discovery loop
- Biologics & Immune-Oncology expertise
- Antibody engineering, linker chemistry, payload conjugation

## CDMO and API

### Advanced Cetner for PR&D and Scale-Up (Delhi NCR, India)

**~100 Scientists**
**PRD & Non GMP Scale up**

- Greater than 1 KL capacity
- 15 reactors ( 20 to 250 L )
- Multiple PRD programs ranging from Phase 1 to Phase 3
- SS, GLR, Hastelloy Reactors
- Material Generation upto 25KG
- FFS Compatible

### GMP CDMO & API Manufacturing Facility (Nanjangud, India)

**900+ MT production capacity**
**785 KL reactor capacity**

- 6 Plants, Kilo Lab & Pilot Plant
- Potent API expertise
- OEB Class 1-4 API potency
- 50 gm - 1.2 Ton GMP Batch
- Digitally Enabled (DCS + QA/QC)

# Drug Discovery Financials : Q1'FY27

| Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 161 | 162 | 174 | *8%* |
| EBITDA | 32 | 42 | 45 | *43%* |
| *EBITDA Margin (%)* | *20%* | *26%* | *26%* | *630 bps* |

- Revenue increased YoY on the back of increase in revenue from biotech and large pharma customers
- EBITDA margins improved YoY due to better revenue mix and forex gain

# Drug Discovery Vision 2030 :
# Triple revenues & maintain profitability




**Revenue:**
**~ 3x of FY24**
**EBITDA Margin:**
**More than 25%**

# Drug Discovery Services: Leverage Large Pharma potential

**Growth driver:**

- **Add Large Pharma**

## Biosecure Act

- **Biosecure ACT becomes law** in the Unites states
- Federal agencies must not enter in contract with a biotechnology company of concern

- **Execute strategy on Large Pharma**
- **Build Footprint in EU**
- **Introduce ADCs, mAbs, and Biologics platforms**

# Drug Discovery Services: Expansion at current and new sites to enable revenue growth

**Expansion at current sites, Greater Noida & Bengaluru**

**Expansion at new site, Devanahalli, Bengaluru**

**Capacity** : **1,000** FTE's ( FY25 ) → **2,000** FTE's ( FY28 ) → **4,000** FTE's ( FY30 )

**Increasing capacity in a phased manner ; Total Capex USD 150 Mn. ( Expect RoCE > 20% )**

# Drug Discovery Services: Added capability in Biologics through strategic partnership with Pierre Fabre

- Expanded TAM by USD 1.4 Bn. in mAbs and ADCs
- Added strategic footprint in the EU
- Enhanced domain expertise in ADC
- Unique & cost-effective delivery model

**Integration complete; Investing in Business development team**

# API Financials : Q1'FY27

| Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 141 | 156 | 135 | *(4%)* |
| EBITDA | 22 | 22 | 19 | *(12%)* |
| *EBITDA Margin (%)* | *15%* | *14%* | *14%* | *(130) bps* |

- Industry wide pricing pressure continues. Focus to increase revenue mix from Custom manufacturing
- EBITDA margins marginally lower YoY due to lower revenue and increase in raw material cost
- Expect margin pressure in FY27 due to raw material cost inflation on account of current ongoing middle east conflict. Focusing on high margin products to offset the impact.

# API Vision 2030 :
# Double revenues and increase profitability

Revenue growth is challenging due to pricing pressure. Custom manufacturing to increase utilization

Margins on track

Revenue:
**2x of FY24**
EBITDA Margin:
**More than 15%**



# API
# Grow CDMO and custom manufacturing in API

**Growth driver:**

- **Grow CDMO API**


- **Further Strengthen CDMO:** Leverage GMP manufacturing capabilities for Innovative New Chemical Entities
- **Custom Manufacturing:** Partner with large pharma to manufacture products requiring life cycle management
- **China plus one strategy:** Resilient supply chain through increased backward integration & diversified supplier base

- **Completed sale and transfer of API business to "Jubilant Biosys",** wholly owned subsidiary of company
- Combined platform to **improve operational efficiency** and **superior brand recall of "Jubilant Biosys"**
- **Increase asset utilization of API business by improving revenue mix towards Custom manufacturing & CDMO**


Generics

# Global Generics market expected to grow by ~ 5% to 6%




## Growth Drivers and Trends

**Developed Market**

- US market to grow at 2%
- Non-US market to grow by 5 - 7%

**India Market**

- India market to grow ~ 8-9%
- Brand building and in-clinic effectiveness are is key drivers

# We are building a growing, profitable & agile business model

## Non-US international market

- Broad therapeutic coverage - CVS, CNS, GI and multi specialty
- Projected to reach 2 key markets with triple digit revenue in INR Cr., Build total of 3 - 4 markets (B2B2C)
- Global presence in 50+ markets - US, Europe, Canada, Japan, Australia



## US Market

- Focusing on profitable portfolio and customers
- Serving through Roorkee facility & CMO network

## Indian Market

- Developing 3 to 4 profitable therapeutic areas / indications

# Generics Financials : Q1'FY27

| Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 166 | 214 | 173 | *4%* |
| EBITDA | 12 | 32 | 4 | *(65%)* |
| *EBITDA Margin (%)* | *7%* | *15%* | *2%* | *(480) bps* |

- Revenue grew marginally on YoY. Launched 2 new products in Q1'FY27.
- EBITDA margins lower YoY due to change in product mix. Trailing 12 month margin at ~ 10%. Expect margins to improve in subsequent quarters

# Generics Vision 2030:
# Reach top quartile profitability for similar size companies




Revenue :
**~2x of FY24**
EBITDA Margin :
**15% to 17%**

# Generics
# Growth Drivers

## Launch
## 6 to 8 new products annually

- Relaunch dormant ANDAs from Roorkee and CMO network
- Secure ANDAs approvals
- In license and acquire targeted ANDAs

## Grow the profitable
## Non-US international market

- Launch 6 to 8 new products every year
- Scale 3 to 4 key markets

## Build branded
## business

- Build presence in Diabetes, Dyslipidemia and Hypertension
- Scale in weight management
- Grow 1.5 times the Industry growth rate


Proprietary
Novel Drugs

# Proprietary Novel Drugs



- **Develop precision oral medicines** with enhanced safety and therapeutic efficacy
- **Focused on specific set of patients**, not responding to other therapies
- **Low-cost in-house discovery engine** to generate drug candidates, validated through partnerships
- **Guided by leading oncologists** from World renowned institutions
- **FDA Orphan drug designations** for leading programs JBI-802 and JBI-778

# JBI-802 to address unmet medical needs in difficult to treat cancers




**Blood Cancer**

*ET/MPN*

- **Company sponsored Phase I/II trial underway**
- Highly differentiated for safety and efficacy than peers
- Total Addressable Market in US ~ USD 5 Bn.

**Lung Cancer**

*NSCLC*

- **Investigator led trial initiated**
- Demonstrated clinical efficacy in two NSCLC patients in phase 1 study
- Total Addressable Market in US ~ USD 3.1 Bn.

**Leukemia**

*Post MPN AML*

- **Investigator led trial under planning**
- Blood cancer progression to Leukemia is a serious complication
- Total Addressable Market in US ~ USD 0.8 Bn.

# JBI -802 has demonstrated rapid, durable platelet normalization in Essential Thrombocythemia patients



*Image only for reference*

- **Essential Thrombocythemia (ET)** is a WHO-defined myeloproliferative neoplasm (blood cancer) characterized by elevated platelets, with risks of thrombosis e.g., stroke, bleeding (hemorrhage) and progression to myelofibrosis or Leukemia, representing **a meaningful unmet need and commercial opportunity**
- Anagrelide is the only FDA approved drug for ET and has a boxed warning. Other drugs such as Hydroxyurea are used off-label but have poor patient outcomes
- No FDA approvals for ~30 years which means **a field ripe for targeted therapy with ~150,000 patients in U.S alone**

- **Early Phase I/II data from JBI-802 demonstrates rapid, durable, dose-dependent platelet reduction, with potential superior safety profile**

# JBI-778 to address unmet medical needs in difficult to treat cancers

**JBI-778**

**Phase I trial underway**

**Lung Cancer**

*NSCLC with EGFR mutation*

- Total Addressable Market in US: USD 2.0 Bn.

**Brain Tumor**

*HGG*

- High unmet need with no effective treatment option
- Total Addressable Market in US: USD 1.7 Bn.

**Head & Neck cancer**

*ACC*

- Chemotherapy, current treatment option has low efficacy
- Highly sensitive to treatment mechanism of JBI-778

**Company sponsored First-in- human Phase I trial ongoing in India**

# Proprietary Novel Drugs Financials : Q1'FY27

| Particulars ( Rs. Cr.) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | |
| EBITDA | (6) | (7) | (8) | *(23%)* |

- Continue to invest in a calibrated manner in two lead programs

# Proprietary Novel Drugs to explore monetization

- Expect clinical data readouts in CY 2026
- **Explore monetization through licensing or external fund raising**

# Consolidated Reported Financials – Q1'FY27

## *Solid revenue growth (YoY) across all business segments*

| Particulars ( Rs. Cr. ) | Q1'FY26 | Q4'FY26 | Q1'FY27 | Y-o-Y |
|---|---|---|---|---|
| | | | | |
| **Revenue** | **1,901** | **2,290** | **2,229** | *17%* |
| Other Income | 12 | 24 | 20 | |
| **Total Income** | **1,913** | **2,314** | **2,249** | *18%* |
| **EBITDA** | **302** | **363** | **268** | *(11%)* |
| *EBITDA Margin (%)* | *15.8%* | *15.7%* | *11.9%* | *(385) bps* |
| Exceptional Income / (expense) | 0 | (14) | 0 | |
| | | | | |
| **PBT** | **154** | **176** | **86** | |
| **PBT Margin** | *8.1%* | *7.6%* | *3.8%* | |
| **Normalised PBT[1]** | **154** | **190** | **86** | *(44%)* |
| **Normalised PBT Margin** | *8.1%* | *8.2%* | *3.8%* | *(423) bps* |
| | | | | |
| **Reported PAT** | **103** | **119** | **56** | *(45%)* |
| **Reported PAT Margin** | *5.4%* | *5.2%* | *2.5%* | *(285) Bps* |
| **Normalised PAT[2]** | **103** | **129** | **56** | *(45%)* |
| **Normalised PAT Margin** | *5.4%* | *5.6%* | *2.5%* | *(285) bps* |

- **Revenue grew YoY** on the back of strong performance across all business segments, with CDMO Sterile Injectables delivering particularly robust growth
- **Other income for Q1'FY27** includes **grant income** of Rs. **5.6 Cr.** for Line 3, which shall continue for more than 20 years and upto 30 years.
- **EBITDA decreased YoY,** particularly due to unavailability of SPECT products in Radiopharmaceuticals & negligible third-party revenues and higher operating expenses including incremental remediation cost at CMO Montreal
- **Reported PAT decreased YoY** due to lower operating profitability and increase in depreciation for Line 3 in Spokane

*1. Normalised PBT is after adjusting for Exceptional items*
*2. Normalised PAT is after adjusting for Exceptional items and tax*

# Key Ratios

*Net Debt / Ebitda to remain range bound*

| Particulars ( Rs. Cr. ) | Mar 31, 2026 | June 30, 2026 |
|---|---|---|
| **Net Debt** ( On constant currency, Net of DIC ) | 1,952 | 2,338 |
| **Net Debt / Equity** | 0.28 | 0.33 |
| **Net Debt / EBITDA (TTM)** | **1.5** | **1.8** |
| **Interest Coverage Ratio** | 6.3 | 6.0 |
| | | |
| **Long Term Capex Creditors** | 711 | 710 |

- **Net debt / Ebitda to remain range bound**
- **Key ongoing Capex Projects Include**

  New (6) PET Manufacturing Facilities
  CDMO SI, Spokane Line 4
  CDMO SI, Montreal Line 5
  Allergy Immunotherapy facility upgrade
  New Product Development

Interest Coverage Ratio = EBITDA / Interest
Exchange Rate : 1 USD = INR 94.84 on Mar 31,2026, 1 USD = INR 94.66 on June 30,2026

# Sustainability

NSE Sustainability Ratings & Analytics
Category I ERP
**ESG Score 72 % Leader**

dun & bradstreet
ESG Horizons: Now and Next
**Recognized – Leading ESG entity**

BRONZE | Top 35%
ecovadis
Sustainability Rating
JUL 2025
**EcoVadis Score 61 %**

S&P Global
Dow Jones Sustainability Indexes
**DJSI Score 57%**

Crisil ESG Ratings & Analytics
ESG Score 63%

**FY25 Sustainability Report published**

**Assured by EY**


FY25 **Sustainability Linked Loan** KPIs Assurance completed by EY

**2001** – ISO 14000 Certification

**2002** – Sustainability Policy Adopted

**2003** – Sustainability Report Released

**2005** – Became GRI Organization Stakeholder Member

**2008** – Jubilant Bhartia Foundation CSR Wing Launched

**2009** – Climate Change Mitigation and Green Supply Chain Policy

**2010** – Became UNGC Signatory and Participation in CDP

**2013** – 1st EvoVadis Review conducted

**2015** – SoFI Sustainability Software Launched

**2019** – Sustainability Goals created aligned with UNSDG

**2021** – Dow Jones Sustainability Index (DJSI)

**2024** – Investment in renewable energy

*Monitoring yearly sustainability targets*

# Summary – Q1'FY27

1. **Radio Pharmaceuticals** : Ruby-Fill® maintaining **growth momentum.** Revenue and EBITDA to normalize from H2'FY27
   **Radio Pharmacies** : Competitive intensity higher in SPECT, **PET products revenue** continue to grow

2. **Allergy Immunotherapy** : Revenue grew YoY; EBITDA margins decreased due to lower production.

3. **CDMO Sterile Injectable** : **Strong revenue growth from Line 3 tech transfer programs.**
   Commercial batch production started for existing SPECT radiopharmaceutical products at CDMO Montreal

4. **CRDMO DDS:** Steady growth & profitability improvement amid intensifying competition. **Medium term outlook continues to be positive**
   **CRDMO API :** Focus on profitable products. **Taking initiatives to build custom manufacturing business**

5. **Generics** : Improved **growth & profitability outlook**

6. **Prop Novel Drugs** : **Patient dosing** progressing in both lead programs

# Financial Results Table

| Total Income ( Rs. Cr. ) | Q1'FY26 | | Q4'FY26 | | Q1'FY27 | growth |
|---|---|---|---|---|---|---|
| **Revenue (A)** | **1,901** | | **2,290** | | **2,229** | ***17%*** |
| **a. Radiopharma** | **869** | | **990** | | **1,022** | ***18%*** |
| *Radiopharmaceuticals* | 271 | | 319 | | 322 | *19%* |
| *Radiopharmacies* | 598 | | 671 | | 700 | *17%* |
| **b. Allergy Immunotherapy** | **181** | | **218** | | **214** | ***18%*** |
| **c. CDMO Sterile Injectables** | **370** | | **535** | | **496** | ***34%*** |
| **d. CRDMO** | **302** | | **318** | | **309** | ***2%*** |
| *Drug Discovery Services* | 161 | | 162 | | 174 | *8%* |
| *CDMO – API* | 141 | | 156 | | 135 | *(4%)* |
| **e. Generics** | **166** | | **214** | | **173** | ***4%*** |
| **f. Proprietary Novel Drugs** | **0** | | **0** | | **0** | |
| *Unallocable Corporate Income* | 13 | | 15 | | 14 | *11%* |
| **Other Income (B)** | **12** | | **24** | | **20** | ***66%*** |
| **Total Income (A+B)** | **1,913** | | **2,314** | | **2,249** | ***18%*** |

| EBITDA ( Rs. Cr. ) | Q1'FY26 | Margin | Q4'FY26 | Margin | Q1'FY27 | Margin |
|---|---|---|---|---|---|---|
| **a. Radiopharma** | **136** | ***16%*** | **116** | ***12%*** | **121** | ***12%*** |
| *Radiopharmaceuticals* | 126 | *46%* | 106 | *33%* | 110 | *34%* |
| *Radiopharmacies* | 10 | *2%* | 11 | *2%* | 12 | *2%* |
| **b. Allergy Immunotherapy** | **63** | ***35%*** | **90** | ***41%*** | **66** | ***31%*** |
| **c. CDMO Sterile Injectables** | **62** | ***17%*** | **91** | ***17%*** | **45** | ***9%*** |
| **d. CRDMO** | **54** | ***18%*** | **64** | ***20%*** | **64** | ***21%*** |
| *Drug Discovery Services* | 32 | *20%* | 42 | *26%* | 45 | *26%* |
| *CDMO – API* | 22 | *15%* | 22 | *14%* | 19 | *14%* |
| **e. Generics** | **12** | ***7%*** | **32** | ***15%*** | **4** | ***2%*** |
| **f. Proprietary Novel Drugs** | **(6)** | | **(7)** | | **(8)** | |
| *Unallocable Corporate ( Expenses) / Income* | (18) | | (22) | | (25) | |
| **Total EBITDA** | **302** | ***15.8%*** | **363** | ***15.7%*** | **268** | ***11.9%*** |

**Other income for Q1'FY27** includes **grant income** of Rs. **5.6 Cr.** for Line 3, which shall continue for more than 20 years and upto 30 years

# Vision 2030

| | |
|---|---|
| Revenue | Reach **2x** *from FY24 to FY30* |
| EBITDA Margin | **23% to 25%** *by FY30* |
| Net Debt | **Zero** *by FY30* |
| RoCE | **High Teens** *by FY30* |

# Annexure

# Executive Leadership Team

**Shyam S Bhartia**
Chairman

**Hari S Bhartia**
Co-Chairman

**Priyavrat Bhartia**
Managing Director

**Arjun S Bhartia**
Joint Managing Director

**Shantanu Jha**
Group CHRO & Acting CEO,
Jubilant Biosys

**Ashish Mukkirwar**
CFO

# Executive Leadership Team

**Harsher Singh**
CEO - Jubilant Radiopharma

**Chris Preti**
CEO - CDMO Sterile Injectables

**Dr Jaidev Rajpal**
CEO - Jubilant Generics

**Kyle Ferguson**
CEO - Allergy Immunotherapy

**Daniel J. O'Connor**
CEO – Jubilant Therapeutics

# Shareholding Pattern

## As on 30th June 2026



# Glossary

| Abbreviation | Details |
|---|---|
| CVS | Cardiovascular System |
| CNS | Central Nervous System |
| CDMO | Contract Development Manufacturing Organization |
| CRDMO | Contract Research & Development Manufacturing Organization |
| F18 | Fluorine-18 Radioisotope |
| PSMA | Prostate Specific Membrane Antigen |
| Lu177 | Lutetium-177 Radioisotope |
| Ac225 | Actinium-225 Radioisotope |
| MAA | Macro Aggregated Albumin |
| DTPA | Diethylenetriaminepentacetic Acid-Chelating Agent |
| HICON | Pharmaceutical Grade Radioactive Iodine |
| I 131 | Iodine-131 Radioisotope |
| MIBG | Metaiodobenzylguanidine |
| USP (USP 825 Guideline) | U.S. Pharmacopeia (USP) general chapter ,825 (Related to Radiopharmaceuticals: Preparation, Compounding, Dispensing, and Repackaging) |
| Ga 68 | Gallium-68 Radioisotope |
| Rb | Rubidium (chemical element) |
| Sr | Strontium (chemical element) |
| Cu 64 | Copper-64 Radioisotope |
| NRC | Nuclear Regulatory Commission (U.S.) |
| GPOs | Group Purchasing Organisation |
| IDNs | Integrated Delivery Network |
| SCIL | Sublingual immunotherapy (Allergy treatment - Dust mites & Seasonal allergy) |
| SCIT | Subcutaneous Immunotherapy (Allergy treatment Insect venom, pet dander, Mold, and other allergens) |
| APAC | Asia Pacific |
| MEA | Middle East Africa |
| NSCLC | Non-small cell lung cancer |
| SCLC | Small cell lung cancer |

| Abbreviation | Details |
|---|---|
| MEA | Middle East Africa |
| LATAM | Latin America |
| LOE | Loss of exclusivity |
| FDA (US) | U.S. Food and Drug Administration |
| PMDA (Japan) | Pharmaceutical and Medical Device Agency |
| KFDA (Korea) | Korea Food Development Authority |
| ANVISA (Brazil) | Brazilian Health Regulatory Agency |
| TGA (Australia) | Therapeutic Goods Administration |
| API | Active Pharmaceutical Ingredient |
| MENA | Middle East North Africa |
| GMP | Good Manufacturing Practices |
| B2B2C | Business-to-Business-to-Consumer |
| B2B | Business-to-Business |
| ET/MPN | Essential thrombocythemia / Myeloproliferative neoplasm (rare chronic blood cancer) |
| coREST Inhibitor/ | CRISPR-Cas9 Endomorphic RNA Symptomatic Inhibitor (RNA based therapy targeting genetic disease) |
| Epigenetic Modulating Agent | Medications that modify gene expression patterns |
| PRMT5 Inhibitor | Protein Arginine Methyltransferase 5 inhibtor (Blocks enzyme activity involved in adding methyl groups to arginine residues, affecting gene expression regulation) |
| Brain Penetrant | Cerebral blood flow enhancers or cognitive-enhancing drugs (supplements) |
| PD-L1 Inhibitor | Programmed death Ligand-1 inhibitor (blocks the PD-L1 pathway, enhancing immune response against cancer cells) |
| PAD4 Inhibitor | poly(ADP-ribose) polymerase 4 inhibitor (Disrupts DNA repair mechanisms in cancer cells, leading to their death) |
| LSD1/HDAC6 inhibitor | Lysine specific demethylase 1/Histone deacetylase 6 inhibtor (Blocks enzymes involved in modifying histones, impacting gene expression regulation in cancer therapy) |
| NSCLC | Non-small cell lung cancer |
| SCLC | Small cell lung cancer |


Thanks!